Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia

PURPOSE: Tamoxifen administered for 5 years at 20 mg/d is effective in breast cancer treatment and prevention, but toxicity has limited its broad use. Biomarker trials showed that 5 mg/d is not inferior to 20 mg/d in decreasing breast cancer proliferation. We hypothesized that a lower dose given for...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: DeCensi, Andrea, Puntoni, Matteo, Guerrieri-Gonzaga, Aliana, Caviglia, Silvia, Avino, Franca, Cortesi, Laura, Taverniti, Cristiana, Pacquola, Maria Grazia, Falcini, Fabio, Gulisano, Marcella, Digennaro, Maria, Cariello, Anna, Cagossi, Katia, Pinotti, Graziella, Lazzeroni, Matteo, Serrano, Davide, Branchi, Daniela, Campora, Sara, Petrera, Marilena, Buttiron Webber, Tania, Boni, Luca, Bonanni, Bernardo
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2019
Témata:
Original Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6601429/
https://ncbi.nlm.nih.gov/pubmed/30973790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.01779
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky